PMID- 24482752
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20210203
LR  - 20211021
IS  - 2162-4011 (Print)
IS  - 2162-402X (Electronic)
IS  - 2162-4011 (Linking)
VI  - 2
IP  - 11
DP  - 2013 Nov 1
TI  - CD137L-stimulated dendritic cells are more potent than conventional dendritic 
      cells at eliciting cytotoxic T-cell responses.
PG  - e26859
LID - e26859
AB  - Dendritic cells (DCs) are highly potent initiators of adaptive immune responses 
      and, as such, represent promising tools for immunotherapeutic applications. 
      Despite their potential, the current efficacy of DC-based immunotherapies is 
      poor. CD137 ligand (CD137L) signaling has been used to derive a novel type of DCs 
      from human peripheral blood monocytes, termed CD137L-DCs. Here, we report that 
      CD137L-DCs induce more potent cytotoxic T-cell responses than classical DCs 
      (cDCs). Furthermore, in exploring several DC maturation factors for their ability 
      to enhance the potency of CD137L-DCs, we found the combination of interferon gamma 
      (IFNgamma) and the mixed Toll-like receptor (TLR)7/8 agonist R848, to display the 
      highest efficacy in potentiating the T-cell co-stimulatory activity of 
      CD137L-DCs. Of particular importance, CD137L-DCs were found to be more efficient 
      than cDCs in activating autologous T cells targeting the cytomegalovirus 
      (CMV)-derived protein pp65. Specifically, CD137L-DC-stimulated T cells were found 
      to secrete higher levels of IFNgamma and killed 2-3 times more HLA-matched, 
      pp65-pulsed target cells than T cells activated by cDCs. Finally, in addition to 
      stimulating CD8(+) T cells, CD137L-DCs efficiently activated CD4(+) T cells. 
      Taken together, these findings demonstrate the superior potency of 
      CD137L-stimulated DCs in activating CMV-specific, autologous T cells, and 
      encourage the further development of CD137L-DCs for antitumor immunotherapy.
FAU - Harfuddin, Zulkarnain
AU  - Harfuddin Z
AD  - Department of Physiology; National University of Singapore; Singapore ; 
      Immunology Programme; National University of Singapore; Singapore ; NUS Graduate 
      School for Integrative Sciences and Engineering; National University of 
      Singapore; Singapore.
FAU - Kwajah, Shaqireen
AU  - Kwajah S
AD  - Department of Physiology; National University of Singapore; Singapore.
FAU - Chong Nyi Sim, Adrian
AU  - Chong Nyi Sim A
AD  - Department of Microbiology; National University of Singapore; Singapore ; 
      Immunology Programme; National University of Singapore; Singapore.
FAU - Macary, Paul Anthony
AU  - Macary PA
AD  - Department of Microbiology; National University of Singapore; Singapore ; 
      Immunology Programme; National University of Singapore; Singapore ; NUS Graduate 
      School for Integrative Sciences and Engineering; National University of 
      Singapore; Singapore.
FAU - Schwarz, Herbert
AU  - Schwarz H
AD  - Department of Physiology; National University of Singapore; Singapore ; 
      Immunology Programme; National University of Singapore; Singapore ; NUS Graduate 
      School for Integrative Sciences and Engineering; National University of 
      Singapore; Singapore.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20131111
PL  - United States
TA  - Oncoimmunology
JT  - Oncoimmunology
JID - 101570526
PMC - PMC3897521
OTO - NOTNLM
OT  - CD137
OT  - CMV
OT  - T-cell responses
OT  - cytomegalovirus
OT  - dendritic cell
OT  - immunotherapy
EDAT- 2014/02/01 06:00
MHDA- 2014/02/01 06:01
PMCR- 2013/11/11
CRDT- 2014/02/01 06:00
PHST- 2013/07/27 00:00 [received]
PHST- 2013/10/15 00:00 [revised]
PHST- 2013/10/17 00:00 [accepted]
PHST- 2014/02/01 06:00 [entrez]
PHST- 2014/02/01 06:00 [pubmed]
PHST- 2014/02/01 06:01 [medline]
PHST- 2013/11/11 00:00 [pmc-release]
AID - 2013ONCOIMM0208R [pii]
AID - 10.4161/onci.26859 [doi]
PST - ppublish
SO  - Oncoimmunology. 2013 Nov 1;2(11):e26859. doi: 10.4161/onci.26859. Epub 2013 Nov 
      11.